Tag Archives: bedaquiline

China study supports use of repurposed drug, shorter regimen for MDR TB treatment

By on .

Patients treated for multidrug-resistant tuberculosis with an experimental regimen containing a repurposed drug for a year had similar rates of successful outcomes as patients treated with the standard available regimen over the course of 18 months, a study across multiple health facilities in China has found. The only significant difference between the outcomes of the […]

WHO finalizes MDR-TB treatment guidance recommending shift from injections

By on .

Including recommendations that injected drugs with permanent debilitating side effects not be included in longer treatment regimens against multidrug-resistant tuberculosis, and the inclusion of the most recently added drugs, bedaquiline and delamanid in those treatments, the World Health Organization today released updated guidelines for treating TB that does not respond to first line treatments. The […]

WHO releases updated drug-resistant TB guidelines, removing toxic injectables from recommended treatments

By on .

With the release of a “pre-final text” of updated guidelines for treatment of multidrug- and rifampicin-resistant tuberculosis, the World Health Organization made official substantial changes to its recommendations that the agency first announced in August. The changes, announced in a “rapid communication,” which the WHO said was intended to give TB programs time to plan for […]

Findings indicate two newest TB drugs, bedaquiline and delamanid in combination safe, promising for patients with few options

By on .

A study following outcomes of 28 patients with drug-resistant tuberculosis in three countries with high burdens of the disease found what the researchers cite as strong evidence that a combination of the two newest TB drugs could be part of a safe and effective treatment regimen. The  drugs, bedaquiline — which was approved by the […]

Access to medicine, diagnostics and human rights . . . We’re reading how to fight TB

By on .

Just 2 percent of people with the severest cases of drug-resistant TB currently have access to new, more effective treatments that could save their lives – Remember the excitement a couple of years back when the first new kinds of drugs to treat TB to be developed in half a century were approved? When delamanid […]

TB advocates call on organizations, leaders to work together, speed access to existing treatments for drug resistant tuberculosis

By on .

They would like an answer on March 24 When World TB Day next Tuesday commemorates the discovery in 1882 of the bacteria that causes the disease, announcements and op-ed pieces will note the progress that has been made since, and will certainly call for more. A group of 89 organizations that last week sent a […]

Tuberculosis R&D must be U.S. diplomatic priority, say global health leaders

By on .

Along with maintaining funding for fighting global tuberculosis, the United States government must better coordinate with the most affected countries on TB research and development, said global health leaders Monday at a Center for Strategic and International Studies event in Washington, examining challenges to global tuberculosis efforts. This point, along with the recommendation that the […]

TAG’s TB drug guide aims to equip activists

By on .

While the impact of tuberculosis grew over the last decades of the 20th century, with drug resistant forms of the disease and HIV fueling its spread and slowing cures, the drugs used to treat TB have not changed. Bedaquiline and delaminid are the only new TB drugs to have been approved in over forty years, […]

TB drug approvals, distribution deal inches options forward, but MDR TB treatment access still uncertain where needed most

By on .

Last week’s developments in TB treatment included the announcement that bedaquiline, the currently most promising medicine for multi-drug-resistant tuberculosis, will become available to patients in 130 low- and middle-income countries through the Stop TB Partnership’s Global Drug Facility. That good news for multidrug-resistant TB patients, many of whom have run out of other options, was […]

Access to treatments for MDR TB, hepatitis C, other health threats set to expand with UNITAID grants targeting market barriers

By on .

The first new tuberculosis drug in more than 40 years, a treatment for hepatitis C currently priced in the United States at $84,000, and an early infant diagnostic test for HIV are among the breakthrough medicines and technologies the global health financing organization UNITAID is aiming to make available to people in low- and middle-income […]